Litcius/Paper detail

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy

Gargi Banerjee, Gareth Ambler, Ashvini Keshavan, Ross W. Paterson, Martha Foiani, Jamie Toombs, Amanda Heslegrave, John Dickson, Francesco Fraioli, Ashley M. Groves, Michael P. Lunn, Nick C. Fox, Henrik Zetterberg, Jonathan M. Schott, David J. Werring

2020Journal of Alzheimer s Disease71 citationsDOIOpen Access PDF

Abstract

BACKGROUND: There is limited data on cerebrospinal fluid (CSF) biomarkers in sporadic amyloid-β (Aβ) cerebral amyloid angiopathy (CAA). OBJECTIVE: To determine the profile of biomarkers relevant to neurodegenerative disease in the CSF of patients with CAA. METHODS: We performed a detailed comparison of CSF markers, comparing patients with CAA, Alzheimer's disease (AD), and control (CS) participants, recruited from the Biomarkers and Outcomes in CAA (BOCAA) study, and a Specialist Cognitive Disorders Service. RESULTS: We included 10 CAA, 20 AD, and 10 CS participants (mean age 68.6, 62.5, and 62.2 years, respectively). In unadjusted analyses, CAA patients had a distinctive CSF biomarker profile, with significantly lower (p < 0.01) median concentrations of Aβ38, Aβ40, Aβ42, sAβPPα, and sAβPPβ. CAA patients had higher levels of neurofilament light (NFL) than the CS group (p < 0.01), but there were no significant differences in CSF total tau, phospho-tau, soluble TREM2 (sTREM2), or neurogranin concentrations. AD patients had higher total tau, phospho-tau and neurogranin than CS and CAA groups. In age-adjusted analyses, differences for the CAA group remained for Aβ38, Aβ40, Aβ42, and sAβPPβ. Comparing CAA patients with amyloid-PET positive (n = 5) and negative (n = 5) scans, PET positive individuals had lower (p < 0.05) concentrations of CSF Aβ42, and higher total tau, phospho-tau, NFL, and neurogranin concentrations, consistent with an "AD-like" profile. CONCLUSION: CAA has a characteristic biomarker profile, suggestive of a global, rather than selective, accumulation of amyloid species; we also provide evidence of different phenotypes according to amyloid-PET positivity. Further replication and validation of these preliminary findings in larger cohorts is needed.

Topics & Concepts

Cerebral amyloid angiopathyCerebrospinal fluidPathologyMedicineAmyloid (mycology)AngiopathyDementiaDiseaseEndocrinologyDiabetes mellitusIntracerebral and Subarachnoid Hemorrhage ResearchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy | Litcius